Bullish indicating open at $55-$60, IPO prices at $37
Kevin Fitzgerald, Chief Scientific Officer and Executive Vice President at Alnylam Pharmaceuticals (NASDAQ:ALNY), a $32.27 billion market cap biotech company that has delivered an impressive 62.3% return over the past year, recently reported several stock transactions involving the company’s common stock. According to InvestingPro analysis, the stock is currently trading above its Fair Value. According to the SEC filing, Fitzgerald sold shares totaling $669,303 over two days, with prices ranging from $239.24 to $248.36 per share.
On March 3, Fitzgerald executed sales amounting to $180,401, with individual transactions priced between $242.37 and $248.36. The following day, March 4, he sold additional shares totaling $488,902, with prices ranging from $239.24 to $245.30.
These transactions were made under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for selling stocks to avoid accusations of insider trading. Following these transactions, Fitzgerald holds 13,501 shares directly. For deeper insights into insider trading patterns and comprehensive analysis, including 8 additional ProTips, check out the full research report available on InvestingPro.
In other recent news, Alnylam Pharmaceuticals has been in the spotlight with several significant developments. The company announced its fourth-quarter earnings, with projected net product revenues for 2025 ranging between $2.05 billion and $2.25 billion, slightly above the consensus estimate of $2.14 billion. Analysts from H.C. Wainwright have raised their price target for Alnylam to $500, maintaining a Buy rating, emphasizing the potential of AMVUTTRA and its successor, nucresiran, in treating transthyretin-mediated diseases. RBC Capital Markets reiterated its Outperform rating with a $310 target, citing Alnylam’s robust research and development pipeline. Piper Sandler also maintained an Overweight rating with a $304 target, highlighting the expected approval of AMVUTTRA for ATTR-CM by March 2025, which could significantly boost sales. The company is preparing for several upcoming clinical trials, including Phase 3 trials for nucresiran and zilebesiran. Alnylam’s recent Research and Development Day further showcased its diverse pipeline, including new targets for obesity and type 2 diabetes. Additionally, the company announced the upcoming retirement of co-founder Dr. Phillip A. Sharp (OTC:SHCAY) from its Board of Directors in May 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.